Summary of opinion: Yselty, 17/10/2024 Positive
Submitted by Anonymous (not verified) on 18 October 2024 - 11:00
Summary of opinion: Yselty, 17/10/2024 Positive
Translarna: EMA re-confirms non-renewal of authorisation of Duchenne muscular dystrophy medicine
Submitted by Anonymous (not verified) on 18 October 2024 - 11:00
Translarna: EMA re-confirms non-renewal of authorisation of Duchenne muscular dystrophy medicine
Summary of opinion: Tevimbra, 17/10/2024 Positive
Submitted by Anonymous (not verified) on 18 October 2024 - 11:00
Summary of opinion: Tevimbra, 17/10/2024 Positive
Summary of opinion: Kisqali, 17/10/2024 Positive
Submitted by Anonymous (not verified) on 18 October 2024 - 10:48
Summary of opinion: Kisqali, 17/10/2024 Positive
Human medicines European public assessment report (EPAR): Zytiga, abiraterone, Date of authorisation: 05/09/2011, Revision: 28, Status: Authorised
Submitted by Anonymous (not verified) on 18 October 2024 - 10:15
Human medicines European public assessment report (EPAR): Zytiga, abiraterone, Date of authorisation: 05/09/2011, Revision: 28, Status: Authorised
Human medicines European public assessment report (EPAR): Velcade, bortezomib, Date of authorisation: 26/04/2004, Revision: 46, Status: Authorised
Submitted by Anonymous (not verified) on 18 October 2024 - 10:10
Human medicines European public assessment report (EPAR): Velcade, bortezomib, Date of authorisation: 26/04/2004, Revision: 46, Status: Authorised
Medicinal products for human use: monthly figures - September 2024
Submitted by Anonymous (not verified) on 18 October 2024 - 8:26
Medicinal products for human use: monthly figures - September 2024
Training webinar on Product Management Service (PMS) Product User Interface (PUI), Online, from 16 October 2024, 10:00 (CEST) to 16 October 2024, 11:00 (CEST)
Submitted by Anonymous (not verified) on 18 October 2024 - 7:50
Training webinar on Product Management Service (PMS) Product User Interface (PUI), Online, from 16 October 2024, 10:00 (CEST) to 16 October 2024, 11:00 (CEST)
Human medicines European public assessment report (EPAR): Ciambra, pemetrexed, Date of authorisation: 02/12/2015, Revision: 7, Status: Withdrawn (authorisation)
Submitted by Anonymous (not verified) on 17 October 2024 - 16:40
Human medicines European public assessment report (EPAR): Ciambra, pemetrexed, Date of authorisation: 02/12/2015, Revision: 7, Status: Withdrawn (authorisation)
Babesia (B. microti, B, duncani, B. divergens, and B. venatorum) DNA and RNA - Notified body 2797 - 19/11/2021 - View in the context of the performance evaluation consultation procedure (PECP)
Submitted by Anonymous (not verified) on 17 October 2024 - 16:20
Babesia (B. microti, B, duncani, B. divergens, and B. venatorum) DNA and RNA - Notified body 2797 - 19/11/2021 - View in the context of the performance evaluation consultation procedure (PECP)